^
Association details:
| Biomarker: | PDGFRB C843G |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Drug: | Iclusig (ponatinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia
Excerpt:
More importantly, this is the first report of the mutation of PDGFRBC843G, which caused resistance to ABL TKIs, including imatinib, dasatinib, and ponatinib, but responded to multitarget kinase inhibitor CHZ868.
DOI:
10.1182/blood-2017-11-817514
